DongKook Pharmaceutical Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: South Korea
Identifier: KRX:086450
DongKook Pharmaceutical Co Ltd is a part of the healthcare industry based in Korea. Being a pharmaceutical company, its activities are focused on the research and development of drugs. The company produces superior medicines used favorably by consumers such as Madecassol, which is a drug for wounds and Oramedy, which is a drug for treating stomatitis. It also owns a prefilled syringe system in its second factory, through which it produces various kinds of ultramodern injection agents.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 533 out of 853
Universe
Global Universe 11609 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Theravance Biopharma, Inc. |
30.3
High
|
452 out of 853 |
Green Cross Holdings Corp. |
31.9
High
|
508 out of 853 |
DongKook Pharmaceutical Co., Ltd. |
32.4
High
|
533 out of 853 |
Arcturus Therapeutics Holdings, Inc. |
34.3
High
|
628 out of 853 |
Olema Pharmaceuticals, Inc. |
38.5
High
|
785 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
DongKook Pharmaceutical Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
DongKook Pharmaceutical Co., Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted DongKook Pharmaceutical Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level